SUDA PHARMACEUTICALS LTD

Revolutionising Drug Delivery

Fast tracking pharmaceutical development

Our business model is to develop low-risk pharmaceuticals using novel formulations of existing drugs that are off patent. We re-formulate these drugs to provide patentable products or line extensions for existing franchises.

Well positioned for growth and achieving financial sustainability

- SUDA Ltd is an Australian pharmaceutical company developing novel oro-mucosal sprays of existing drugs
- World-leading OroMist® drug delivery platform incorporating proprietary permeation-enhancing technology
- OroMist® offers advantages of quicker onset of action, enhanced bioavailability, lower doses and patient convenience
- Approx 70 patent families covering the delivery of about 300 high usage off-patent drugs into 'value-added' oral sprays
- Lead product is a first-in-class zolpidem oral spray for treatment of insomnia, ZolpiMist™, approved in the USA
- ZolpiMist™ is partnered with Eddingpharm in China and Teva in Latin America
- Breakthrough sub-lingual antimalarial treatment, ArTiMist®, has successfully completed Phase III and been filed for TGA approval
- Other first-in-class clinical candidates targeting multi-billion dollar markets, including migraine, erectile dysfunction and nausea
- Strategy for value creation through out-licensing, collaborative development and asset sales

Financial Snapshot

ASX: SUD

Revenue FY2017	**A$7.2 m**
Net loss FY2017	**(A$1.2 m)**
Net cash 31 December 2017	**A$0.6 m**
Share price	**A$0.013**
Market capitalisation	**$16 m**
No. of shares in issue	**1,224 m**
52-week high	**$0.03**
52-week low	**$0.01**
Average volume (30-day)	**3.4 m**

Stephen Carter
Chairman & CEO

Joseph Ohayon
CFO & Company Secretary

Nick Woolf
Chief Business Officer

David Phillips
Non-Executive Director

SUDA Pharmaceuticals Ltd
Level 1, Unit 12, Howe Street
Osborne Park, Western Australia 6017
PO Box 1719, Osborne Park BC, WA 6916

Phone, Fax & Email
(T) +61 8 6142 5555
(F) + 61 8 9443 8858
(E) info@sudapharma.com

Website
www.sudapharma.com

Enhancing medicines to benefit patients

SUDA has established a pharmaceutical business based on reformulated products that demonstrate major cost, functional and effectual advantages over competitors, thereby securing patient demand.

Each of our development products addresses an unmet market need with a substantial market size and uses well-characterised molecules that have been approved and accepted by healthcare regulatory authorities in the world's major territories.

Our commercial strategy is to add value to each programme through to a stage where we can secure licensing or collaborative partnerships or alternatively an outright sale.

We have demonstrated our ability to add value through licensing deals with Eddingpharm and Teva, together with a co-development feasibility agreement with Pfizer.

Our business development activities are expected to create further value in 2018.

Product	Active Ingredient	Pre-clinical	Clinical	Approval	Mkt Size	Partnerships (Incl. territories)
*ZolpiMist™	Zolpidem	Insomnia			$2.1bn	Eddingpharm (China) TEVA (Brazil, Mexico, Chile)
ArtiMist®	Artemether	Malaria			>$500m	
SUD-002	Ondansetron	Chemotherapy induced nausea & vomiting			$2.5bn	Kwang Dong (Korea)
SUD-001	Sumatriptan	Migraine headache			$3.2bn	
SUD-003 DuroMist™	Sildenafil	Erectile dysfunction			$4.1bn	
SUD-004	Sildenafil	Pulmonary arterial hypertension			$2.7bn	
SUD-005	Midazolam	Pre-procedural anxiety & epileptic seizures			>$170m	

* SUDA has an exclusive global license to ZolpiMist™ excluding the US and Canada

Our oral spray formulations potentially offer improved efficacy, safety, patient compliance, and patient convenience, compared to the existing marketed products.

ArTiMist® is the world's first sublingual spray for the treatment of *p. falciparum* severe paediatric malaria. The active pharmaceutical ingredient in ArTiMist is artemether, which is a widely used anti-malarial and is currently administered by infusion or orally in a tablet form.

ArTiMist® - helping high-need malaria patients

The Phase III trial of ArTiMist in 150 children with severe malaria across multiple sites in Africa confirmed that the sublingual spray was convincingly superior to the gold standard treatment of intravenous Quinine.

The results have been published in a peer-reviewed journal and presented to the Medicines for Malaria Venture, the WHO and other NGOs.

In April 2017, SUDA submitted a Marketing Authorisation Application to the Australian TGA. The Company expects regulatory approval before the end CY 2018, setting up ArTiMist® for market launch.